TEMENOS
12.1.2021 08:32:36 CET | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that Komerční banka, a member of the Société Générale Group and one of the largest financial institutions in the Czech Republic, has selected Temenos Transact to modernize its retail and corporate banking.
After a rigorous selection process, the bank selected Temenos’ next-generation core banking platform for its modernization journey in the area of account management. Temenos will decrease time to market for innovative current, savings and deposit account services and lending products as well as streamline straight-through-processing across its retail and corporate banking operations.
Komerční banka is a universal bank providing a wide range of services in retail, SME, corporate and investment banking to more than 1.6 million customers. Komerční banka’s services are accessible through a network of more than 240 branches as well as digital banking channels including mobile and internet banking. The modernization of its core system with Temenos constitutes a crucial step in Komerční banka’s long-term strategy to reinforce its leadership in digital banking in the Czech Republic.
Simplification of IT systems and consolidation on Temenos’ platform will enable Komerční banka to bring new products to market faster. It will also enable Komerční banka to deliver an enhanced service with real-time processing and acceleration of customer journeys in retail and corporate segments. Additionally, Temenos’ flexible and agile technology will allow Komerční banka to rationalize its product portfolio and provide a foundation to future-proof business growth.
Komerční banka ranks among the leading banking institutions in the Czech Republic and in Central and Eastern Europe. It has a reputation as a digital leader and Temenos API-first technology will allow Komerční banka to accelerate the development and integration of new services as it continues to improve the experience and value it delivers to customers.
A key factor in Komerční banka’s decision to select Temenos was the rich banking functionality of Temenos Transact for retail and corporate banking. Komerční banka offers a diverse range of deposit, credit, lending and payment services for individuals, small business and corporate customers.
Jan Juchelka, Komerční banka’s Chairman and CEO, commented: “We have selected the new software platform because of its robust design and also its open and modern architecture. We are delighted to have an opportunity to benefit from the expertise and experience of Temenos, whose clients include the world’s largest financial institutions. It is important for us to work with a partner who shares our approach to innovation and who will help us to use the latest technologies now and in the future. Our objective is to achieve the highest level of customer satisfaction in the market. Thanks to the new software platform we can work in agile, flexible, and effective manner and so, ultimately, innovate faster and bring an added value to our clients.”
Jean-Michel Hilsenkopf, Chief Operating Officer, Temenos: “Komerční banka is a large financial institution that has shown a real commitment and appetite for innovation to deliver a market-leading service to its customers. Now, with Temenos cloud-native technology, it can supercharge these efforts and bring new products to market much faster and on a lower cost base. With heightened competition and new regulation putting pressure on margins across the industry, this capability is a huge competitive advantage that will help Komerční banka to grow its client base and ultimately increase market share and profits. Temenos has a long term strategic relationship with Société Générale and Komerční banka is a new step in this long and successful partnership.”
Temenos Transact was recently recognized as a leader in The Forrester Wave™: Digital Banking Processing Platforms Q3 2020 for Corporate Banking and Retail Banking .
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2bn banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
About Komerční banka
Komerční banka is the parent company of KB Group and a member of the Société Générale Group. KB ranks among the leading banking institutions in the Czech Republic, as well as in Central and Eastern Europe. It is a universal bank providing a wide range of services in retail, corporate, and investment banking. Member companies of Komerční banka Group provide additional specialised financial services, such as pension savings and building society schemes, leasing, factoring, consumer lending, and insurance. These are accessible through KB’s branch network, its direct banking channels, and the subsidiaries’ own sales networks. The Bank also provides services in the Slovak Republic through its branch focused on serving corporate clients as well as through selected subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005018/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom